



**Events** 





0.00				
	Ö	10	20	30
		Survival	time, months	
Male, Asymptomatic — M	lale, In bed	<50% of the day	— Female, A	Asymptomatic
	lale, In bed At Risk	> 50% of the day	— Female, S	Symptomatic and ambu
Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Female, Symptomatic and ambulatory	42	23	8	1
Female, In bed <50% of the day	21	7	1	0
	C. conto			

Male, in bed <50 % of the day	23	U	2	U	
Male, In bed > 50% of the day	1	0	0	0	
Female, Asymptomatic	27	13	2	0	
Female, Symptomatic and ambulatory	42	23	8	1	
Female, In bed <50% of the day	21	7	1	0	
I	Events				
	_				

Male, Asymptomatic 

Male, Symptomatic and ambulatory 


Female, Asymptomatic


Female, In bed <50% of the day


Male, In bed <50% of the day 

Male, In bed > 50% of the day 

Female, Symptomatic and ambulatory 







Female, Symptomatic and ambulatory

Female, In bed <50% of the day

Male, Asymptomatic

Female, Asymptomatic


Female, Symptomatic and ambulatory

Female, In bed <50% of the day

Male, Symptomatic and ambulatory


Male, In bed <50% of the day


Male, In bed > 50% of the day





	0	10	20	30
		Survival	time, months	
Male, Asymptomatic — M	ale, In bed <	<50% of the day	— Female, Asy	/mptomatic
	ale, In bed > At Risk	> 50% of the day	— Female, Syr	mptomatic and ambu
Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0

**CUM EVENTS** 









	O	Survival	time, months	00
Male, Asymptomatic — N	/lale, In be	ed <50% of the day	— Female, As	ymptomatic
	/lale, In be	ed > 50% of the day	— Female, Sy	mptomatic and ambu
Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Female, Symptomatic and ambulatory	42	23	8	1
Female, In bed <50% of the day	21	7	1	0
	CLIMAEN	/ENITO		

CUM EVENTS


Male, Asymptomatic 

Male, Symptomatic and ambulatory

Female, Symptomatic and ambulatory


Female, In bed <50% of the day


Male, In bed <50% of the day Male, In bed > 50% of the day Female, Asymptomatic 





**Events** 


rviva		Survival time, months				
omatic	— Male Male, Asymptom		— Female, Asymptomatic	_	- Fem	
At Risk	36	18	6	1		
Events	0	13	24	28		
N	Male, Symptoma	tic and ambulatory				
At Risk	71	20	5	1		
Events	0	39	51	54		
N	Male, In bed <50	% of the day				
At Risk	29	6	2	0		
Events	0	22	26	28		
N	Male, In bed > 50	0% of the day				
At Risk	1	0	0	0		
Events	0	1	1	1		
F	emale, Asympto	omatic				
At Risk	27	13	2	0		
Events	0	4	8	9		
F	emale, Sympton	matic and ambulatory				
At Risk	42	23	8	1		
Events	0	12	22	28		
F	emale, In bed <	50% of the day				
At Risk	21	7	1	0		
Events	0	11	15	16		

















At Risk 228 87 24 3

Events 0 103 148 165




**Events** 







**Events** 




Drug B, II


Drug B, III









		— Drug A	A, II — Drug B, I	— Drug B, III		
А	t Risk					
Drug A, I	35	35	35	30	22	0
Drug A, II	32	32	30	27	23	0
Drug A, III	31	30	29	26	16	0
Drug B, I	33	33	33	28	23	0
Drug B, II	36	36	32	23	17	0
Drug B, III	33	33	30	24	15	0
C	CUM EVENTS					
Drug A, I	0	0	0	4	7	9
Drug A, II	0	0	1	2	3	5
Drug A, III	0	0	1	1	7	10
Drug B, I	0	0	0	3	5	9
Drug B, II	0	0	2	8	12	12
Drug B, III	0	0	2	6	9	12





**Events** 

<u> </u>						
ative	0	5	10	15	20	25
Cumulative In			Months to Dea	ath/Censor		
Cur			Drug A, I — Drug	A, III — Drug E	3, 11	
			Drug A, II — Drug	B, I — Drug E	3, 111	
[	Orug A, I					
At Risk	35	35	35	30	22	0
Events	0	0	0	4	7	9
Ι	Orug A, II					
At Risk	32	32	30	27	23	0
Events	0	0	1	2	3	5
Ι	Orug A, III					
At Risk	31	30	29	26	16	0
Events	0	0	1	1	7	10
Ι	Orug B, I					
At Risk	33	33	33	28	23	0
Events	0	0	0	3	5	9
Ι	Orug B, II					
At Risk	36	36	32	23	17	0
Events	0	0	2	8	12	12
Ι	Orug B, III					
At Risk	33	33	30	24	15	0
Events	0	0	2	6	9	12










 Drug B

 At Risk 102
 102
 95
 75
 55
 0

 Events 0
 0
 7
 27
 47
 60




			16.1			
0.0						
	0	5	10	15	20	25
			Months to De	ath/Censor		
_	Drug A, I	— Drug A, III	— Drug B, II	— death from canc	er death	other causes
_	Drug A, II	— Drug B, I	— Drug B, III			
At	t Risk					
Drug A, I	35	35	35	30	22	0
Drug A, II	32	32	30	27	23	0
Drug A, III	31	30	29	26	16	0
Drug B, I	33	33	33	28	23	0
Drug B, II	36	36	32	23	17	0
Drug B, III	33	33	30	24	15	0
Ev	vents					
Drug A, I	0	0	0	5	13	1€
Drug A, II	0	0	2	5	9	16


Drug A, III

Drug B, I


Drug B, II

Drug B, III









Female Male Male At Risk (Cum. Events) 138 (0) 44 (76) 13 (103) 2 (112) Survival (95% CI) % (100, 100) 42% (34, 52) 15% (9, 23) 4% (1, 12) Female


At Risk (Cum. Events) 90 (0) 1 (53)


Survival (95% CI) % (100, 100)

43 (27) 67% (58, 78)

11 (45) 34% (24, 49)

8% (3, 27)





	Ö	10	20	30
		Survival tir	me, months	
Male, Asymptomatic — N	Male, In bed <50%	% of the day	<ul><li>Female, Asympto</li></ul>	matic
Male, Symptomatic and ambulatory — N	Male, In bed > 50 At Risk (Cum.	•	<ul> <li>Female, Sympton</li> </ul>	natic and ambu
Male, Asymptomatic	36 (0)	18 (13)	6 (24)	1 (28)
Male, Symptomatic and ambulatory	71 (0)	20 (39)	5 (51)	1 (54)
Male, In bed <50% of the day	29 (0)	6 (22)	2 (26)	0 (28)
		- (1)	- (1)	

13 (4)

23 (12)

7 (11)

62% (47, 81)

41% (30, 55)

24% (13, 46)

NA% (NA, NA)

85% (73, 100)

69% (56, 86)

41% (24, 71)

2 (8)

8 (22)

1 (15)

23% (12, 45)

13% (6, 28)

8% (2, 30)

NA% (NA, NA)

52% (30, 88)

34% (21, 57)

18% (6, 49)

0 (9)

1 (28)

0(16)

6% (1, 32)

5% (1, 19)

NA% (NA, NA)

NA% (NA, NA)

NA% (NA, NA)

6% (1, 36)

NA% (NA, NA)

	0.00				
	Ö	10	20	30	
		Survival	time, months		
Male, Asymptomatic	— Male, In bed	<50% of the day	— Female, As	ymptomatic	
Male, Symptomatic and ambulatory	Male, In bed :	> 50% of the day	Female, Sy	mptomatic and amb	)
	At Risk (Cu	ım. Events)			
Male, Asymptomatic	36 (0)	18 (13)	6 (24)	1 (28)	
Male, Symptomatic and ambu	latory 71 (0)	20 (39)	5 (51)	1 (54)	
Male, In bed <50% of the	day 29 (0)	6 (22)	2 (26)	0 (28)	
Male, In bed > 50% of the	day 1 (0)	0 (1)	0 (1)	0 (1)	

27 (0)

21 (0)

5 (100, 100)

5 (100, 100)

5 (100, 100)

5 (100, 100)

5 (100, 100)

Survival (95% CI)

Female, Asymptomatic

Female, In bed <50% of the day

Male, Asymptomatic

Female, Asymptomatic

Female, In bed <50% of the day

Male, In bed <50% of the day

Male, In bed > 50% of the day

Female, Symptomatic and ambulatory 42 (0)

Male, Symptomatic and ambulatory (100, 100)


Female, Symptomatic and ambulatory (100, 100)

87 (103)

24 (148)

3 (165)

No. at Risk (Events) 228 (0)






Female, Asymptomatic

Female, Symptomatic and ambulatory 42 (0)

Female, In bed <50% of the day



	Survival time, months				
Male, Asymptomatic	— Male, In bed <50% of the day	— Female, Asymptomatic			
Male, Symptomatic and ambulatory	<ul><li>Male, In bed &gt; 50% of the day</li><li>No. at Risk (Events)</li></ul>	<ul> <li>Female, Symptomatic and ambul</li> </ul>			
	00 (0)	0 (0 4)			

	0	10	20	30
		Survival	time, months	
Male, Asymptomatic —	Male, In bed	d <50% of the day	Female, As	ymptomatic
Male, Symptomatic and ambulatory —	•	d > 50% of the day sk (Events)	— Female, Sy	mptomatic and ambu
Male, Asymptomatic	36 (0)	18 (13)	6 (24)	1 (28)
Male, Symptomatic and ambulator	ry 71 (0)	20 (39)	5 (51)	1 (54)
Male, In bed <50% of the day	29 (0)	6 (22)	2 (26)	0 (28)

Male, Asymptomatic —	Male, In bed	<50% of the day	— Female, As	ymptomatic
Male, Symptomatic and ambulatory —	Male, In bed No. at Ris	> 50% of the day k (Events)	— Female, Sy	mptomatic and amb
Male, Asymptomatic	36 (0)	18 (13)	6 (24)	1 (28)
Male, Symptomatic and ambulat	ory 71 (0)	20 (39)	5 (51)	1 (54)
Male, In bed <50% of the day	/ 29 (0)	6 (22)	2 (26)	0 (28)

21 (0)

Male, In bed > 50% of the day 1 (0) 0 (1) 0 (1) 0 (1)

23 (12)

7 (11)


27 (0) 13 (4) 2 (8) 0 (9)

8 (22)


1 (15)


1 (28)


0 (16)





**Events** 




























**Events** 





0.00				
	Ö	10	20	30
		Survival	time, months	
Male, Asymptomatic — M	lale, In bed	<50% of the day	— Female, A	Asymptomatic
	lale, In bed At Risk	> 50% of the day	— Female, S	Symptomatic and ambu
Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Female, Symptomatic and ambulatory	42	23	8	1
Female, In bed <50% of the day	21	7	1	0
	C. conto			

Male, in bed <50 % of the day	23	U	2	U	
Male, In bed > 50% of the day	1	0	0	0	
Female, Asymptomatic	27	13	2	0	
Female, Symptomatic and ambulatory	42	23	8	1	
Female, In bed <50% of the day	21	7	1	0	
I	Events				
	_				

Male, Asymptomatic 

Male, Symptomatic and ambulatory 


Female, Asymptomatic


Female, In bed <50% of the day


Male, In bed <50% of the day 


Male, In bed > 50% of the day 

Female, Symptomatic and ambulatory 









Male, Asymptomatic Male, In bed <50% of the day Female, Asymptomatic Male, Symptomatic and ambulatory — Male, In bed > 50% of the day Female, Symptomatic and ambul

maio, cymptomatic and ambanatory		7 0070 0. 11.0 0.00		
	At Risk			
Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Female, Symptomatic and ambulatory	42	23	8	1
Female, In bed <50% of the day	21	7	1	0
	Events			
Male, Asymptomatic	0	13	24	28
Male, Symptomatic and ambulatory	0	39	51	54
Male, In bed <50% of the day	0	22	26	28
Male, In bed > 50% of the day	0	1	1	1
Female, Asymptomatic	0	4	8	9
Female, Symptomatic and ambulatory	0	12	22	28

15

16

Female, In bed <50% of the day